NY-ESO-1 mRNA Neoantigen Vaccine
NY-ESO-1 mRNA neoantigen vaccine expresses human NY-ESO-1 as a GPI-anchored protein and, when packaged into LNP, triggers T-cell responses against tumors.
- The description claims that the vaccine can trigger T-cell responses against tumors presenting NY-ESO-1 neoantigens.
Specifications
- Synthesis scale
- 100 ug, 500 ug, 1 mg
AI Readiness
Good foundation, but some important product data is still missing.
74%